title: The insulin-like growth factor system and the coupling of formation to resorption.
abstract: In the adult skeleton, bone formation is regulated by an event referred to as the coupling of formation to resorption (i.e., formation is linked to resorption), which is thought to be mediated in part by locally produced growth factors. Although human bone cells produce and human bones contain a variety of growth factors, there is sufficient evidence to document an important role for the insulin-like growth factor (IGF) system in mediating this coupling process in bone. Studies on the basic aspects of the IGF system in bone reveal that it is complex and involves a number of components which include the IGF-binding proteins (IGFBPs; mainly IGFBP-3, -4, and -5), specific extracellular IGFBP proteases, and receptors (types 1 and 2). Based on recent experimental evidence from a number of laboratories, we propose the following models of IGF action on the regulation of the coupled increase in bone formation in response to bone resorption: (1) IGF release from bone during bone resorption promotes osteoblasts to initiate cavity refilling; (2) IGF production by osteoclasts creates a population of osteoblasts in proportion to the volume of bone tissue resorbed; and (3) IGF production by stromal cells and osteoblasts predominantly regulates the extent of cavity refill. The amount of growth factor production by osteoblasts and contemporary cells of osteoblast lineage can be further controlled by both systemic and local factors which together determine the eventual level of fill-in of the resorption cavity.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Medicine, Loma Linda University, CA, USA.
authors.forename: J M
authors.initials: JM
authors.lastname: Hayden
authors.forename: S
authors.initials: S
authors.lastname: Mohan
authors.forename: D J
authors.initials: DJ
authors.lastname: Baylink
mesh_terms: D000328:Adult; D001862:Bone Resorption / Q000378:metabolism / Q000503:physiopathology*; D006133:Growth Substances / Q000494:pharmacology; D006728:Hormones / Q000494:pharmacology; D006801:Humans; D018969:Insulin-Like Growth Factor Binding Proteins / Q000378:metabolism / Q000502:physiology*; D007334:Insulin-Like Growth Factor I / Q000378:metabolism / Q000502:physiology*; D007335:Insulin-Like Growth Factor II / Q000378:metabolism / Q000502:physiology*; D010006:Osteoblasts / Q000502:physiology*; D010010:Osteoclasts / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D010012:Osteogenesis / Q000502:physiology*; D010281:Parathyroid Hormone / Q000494:pharmacology; D016474:Weight-Bearing
chemical_list: D006133:Growth Substances; D006728:Hormones; D018969:Insulin-Like Growth Factor Binding Proteins; D010281:Parathyroid Hormone; D007334:Insulin-Like Growth Factor I; D007335:Insulin-Like Growth Factor II